MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Clindamycin 150 mg/mL Injection (Solution, 60 mL)	FIN	F 008 829

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Clindamycin Phosphate, USP	TBD					
Edetate Disodium, USP	0.03	g				
Benzyl Alcohol (Parenteral Application), NF	0.54	mL				
Sterile Water For Injection, USP	50.0	mL				
Sterile Water For Injection, USP	q.s. to 60.0	mL				
Sodium Hydroxide 10% solution	As required					

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Light Sensitive *(protect from light whenever possible):* *Benzyl Alcohol*

Hygroscopic *(protect from moisture whenever possible):* *Edetate Disodium, Clindamycin Phosphate*

Narrow Therapeutic Index *Clindamycin Phosphate*

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Clindamycin 150 mg/mL Injection (Solution, 60 mL)	FIN	F 008 829

SPECIAL PREPARATORY CONSIDERATIONS (CONTINUED)

Suggested Preparatory Guidelines

☐ Non-Sterile Preparation ■ Sterile Preparation

Processing Error / Testing Considerations: To account for processing error, pH testing, sterility and endotoxin testing considerations during preparation, it is suggested to measure an additional **5 to 9%** of the required quantities of ingredients.

Special Instruction: This formula may contain one or more Active Pharmaceutical Ingredients (APIs) that may be classified as hazardous, please refer & verify the current NIOSH list of Antineoplastic and Other Hazardous Drugs in Healthcare Settings. At this time, **General Chapter <800> Hazardous Drugs – Handling in Healthcare Settings** is informational and not compendially applicable unless otherwise specified by regulators and enforcement bodies. For information on the scope, intended applicability, and implementation context for USP General Chapter <800>, see: https://www.usp.org/compounding/general-chapter-hazardous-drugs-handling-healthcare.

This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within *USP 797* and *USP 800*, when handling hazardous drugs. Only trained and qualified personnel must prepare this formula.

All heat stable, reusable materials and equipment must be sterilized and depyrogenated by dry heat sterilization at 250°C for 2 hours prior to use.

Every batch of final product compounded using this procedure must be sterility and endotoxin tested before being dispensed.

All required personal protective equipment (sterile and hazardous if applicable), such as but not limited to, gowns, aprons, sleeves, gloves both inner and outer if applicable, shoe covers, hairnet, head cap, beard cover, eyewear, appropriate face mask, respirator and face shield, etc., where applicable must be worn at all times. In addition, proper personnel cleansing must be done before entering the buffer or clean area.

If applicable, follow all required procedures for hazardous drug handling including but not limited to procurement, transport, storage, preparation, dispensing, administration, clean up (spills) & disposal.

Filter integrity must be validated by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

If you are a registered 503B facility, please refer to all relevant guidance documents including but not limited to the Code of Federal Regulations (CFR), Guidance for Industry (GFIs) and Compliance Policy Guides (CPGs).

Clindamycin Phosphate has a Narrow Therapeutic Index.

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Clindamycin 150 mg/mL Injection (Solution, 60 mL)	FIN	F 008 829

SUGGESTED PREPARATION (for 60 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): ____	Processing Error	Qty. to measure
Clindamycin Phosphate, USP §	TBD				
Edetate Disodium, USP §	0.03	g			
Benzyl Alcohol (Parenteral Application), NF §	0.54	mL			
Sterile Water For Injection, USP §	50.0	mL			
Sterile Water For Injection, USP §	q.s. to 60.0	mL			
Sodium Hydroxide 10% solution §	As required				

* Takes into account increased batch size conversions and density conversions, if required.
§ Weigh / measure just prior to use.

Preparatory Instruction

IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique

1. **Ingredient quantification:**

A. Determine the potency of Clindamycin Phosphate based on the certificate of analysis:

	100%
MINUS	
Water Content (from certificate of analysis)	_____ %
DIVIDED BY	100
EQUALS	
Quantity of Clindamycin Phosphate, in decimal	_____
MULTIPLIED BY	
Assay (base equivalent) on anhydrous basis result (from certificate of analysis)	_____ µg/mg
MULTIPLIED BY (Multiplication factor – µg to grams /mg to grams)	0.001
EQUALS	
i. Potency of Clindamycin Phosphate (Base equivalent) in g/g	_____

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Clindamycin 150 mg/mL Injection (Solution, 60 mL)	FIN	F 008 829

2. **Ingredient quantification:**

A. Determine the quantity (in g) of Clindamycin Phosphate required to make a **Clindamycin** 150 mg/mL Injection, batch size (60 mL):

Quantity of **Clindamycin** required for 60 mL	9.000 g
DIVIDED BY	
Potency of Clindamycin Phosphate (Base equivalent) in g/g (Step 1Ai)	_____
EQUALS	
i. Quantity of Clindamycin Phosphate needed for 60 mL	_____ **g**
MULTIPLIED BY	
Processing error adjustments (5 to 9%)	1.05 to 1.09
EQUALS	
ii. Quantity of Clindamycin Phosphate needed *plus* processing error adjustments	_____ **g**

3. **Equipment sterilization:**

Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.

4. **Medium preparation:**

A. In the given order, sequentially add the following ingredients to the Sterile Water for Injection (50.0 mL *plus* processing error adjustments):

-Clindamycin Phosphate (amount determined in Step 2Aii)
-Benzyl Alcohol (Parenteral Application)
-Edetate Disodium

Specifications: Continuously mix until all solid particles have completely dissolved.

End result: Homogeneous liquid-like solution.

Note: Add the next ingredient, once the previous one has been completely added and dissolved.

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Clindamycin 150 mg/mL Injection (Solution, 60 mL)	FIN	F 008 829

5. **pH testing:**

A. Draw an appropriate amount of the mixture (Step 4A).

B. Test the pH of the sample. It should lie between 5.5 and 7.0.

C. If the pH < 5.5, carefully add, in a dropwise fashion, the Sodium Hydroxide 10% Solution to the mixture:

1. Draw and transfer 1 or 2 drops of the Sodium Hydroxide 10% Solution to the mixture.
2. Stir for at least 5 minutes to evenly disperse the Sodium Hydroxide 10% Solution.
3. Re-test the pH.
4. Continue to add the Sodium Hydroxide 10% Solution until the pH of 5.5 and 7.0 is obtained.

IMPORTANT: Do not allow the pH to rise above 7.0.

6. **Filling to volume:**

A. Add additional Sterile Water for Injection to the above mixture to fill to the required batch size (60.0 mL *plus* processing error adjustments).

Specifications: Continuously mix until homogenous.

End result: Homogeneous liquid-like solution.

7. **Filtering and transferring:**

Aseptically filter the solution through a 0.22-µm sterile filter into the recommended dispensing container (see Packaging requirements). Transfer the remainder into a separate dispensing container. This is to be used as the test sample for sterility and endotoxin testing.

8. **Filter integrity test:**

Validate filter integrity by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

9. **Terminal Sterilization:**

In relation to the chemical composition of the formulation, final packaging, etc., select and validate an end-stage sterilization method and follow the manufacturer's specifications.

10. **Sterility testing:**

Validate the test sample for sterility and endotoxins, in accordance to current USP 797 regulatory guidelines.

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Clindamycin 150 mg/mL Injection (Solution, 60 mL)	FIN	F 008 829

SUGGESTED PRESENTATION

Estimated Beyond-Use Date		24 hours controlled room temperature, 3 days refrigerated, or 45 days frozen, as per USP 797. BUD based on successful endotoxin test result.	Packaging Requirements		Sterile, tightly closed, unit-dose injection vials.
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.	6		Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.
	2	Keep out of reach of children.	7		Do not use if discolored.
	3	Discard container after use.	8		Keep at controlled room temperature, (20°C – 25°C), refrigerated (2°C – 8°C) or frozen (-25°C to -10°C).
	4	Equilibrate to room temperature before use.	9		Hypertonic solution. Diluted before use or inject slowly.
	5	Protect from light.	10		
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.				
Patient Instructions	Contact your pharmacist in the event of adverse reactions.				

Suggested Formula	Clindamycin 150 mg/mL Injection (Solution, 60 mL)	FIN	F 008 829

REFERENCES

1. Parenteral Preparations. In: Allen, LV, Jr. *The Art, Science, and Technology of Pharmaceutical Compounding Fifth Edition.* American Pharmacists Association; 2016: 399.
2. Clindamycin Phosphate. In: Brayfield, A., ed. *Martindale: The Complete Drug Reference, 38th Edition.* London, England: The Pharmaceutical Press; 2014: 269.
3. Clindamycin (Monograph). In: O'Neil MJ. *The Merck Index 15th Edition*. Whitehouse Station, NJ: Merck & Co, Inc.; 2013: #2354.
4. Clindamycin Phosphate. In: Trissel LA. *Trissel's Stability of Compounded Formulations, 5th Edition.* American Pharmaceutical Association; 2012: 125.
5. Clindamycin Phosphate (Monograph). *United States Pharmacopeia XLIII / National Formulary 38.* Rockville, MD. US Pharmacopeial Convention, Inc. 2020: 1069.
6. USP <797>. *United States Pharmacopeia XLIII / National Formulary 38*. Rockville, MD. US Pharmacopeial Convention, Inc. 2020: 7037.